Oligodendroglioma epidemiology and demographics: Difference between revisions
Sara Mohsin (talk | contribs) No edit summary |
Sara Mohsin (talk | contribs) |
||
Line 12: | Line 12: | ||
===Incidence=== | ===Incidence=== | ||
*The incidence of oligodendroglioma and [[anaplastic|anaplastic oligodendroglioma]] is estimated to be 0.32 and 0.17 cases per 100,000 individuals in the United States, respectively.<ref name="pmid21149253">{{cite journal| author=McCarthy BJ, Rankin KM, Aldape K, Bondy ML, Brännström T, Broholm H et al.| title=Risk factors for oligodendroglial tumors: a pooled international study. | journal=Neuro Oncol | year= 2011 | volume= 13 | issue= 2 | pages= 242-50 | pmid=21149253 | doi=10.1093/neuonc/noq173 | pmc=PMC3064625 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21149253 }} </ref> | *The incidence of oligodendroglioma and [[anaplastic|anaplastic oligodendroglioma]] is estimated to be 0.32 and 0.17 cases per 100,000 individuals in the United States, respectively.<ref name="pmid21149253">{{cite journal| author=McCarthy BJ, Rankin KM, Aldape K, Bondy ML, Brännström T, Broholm H et al.| title=Risk factors for oligodendroglial tumors: a pooled international study. | journal=Neuro Oncol | year= 2011 | volume= 13 | issue= 2 | pages= 242-50 | pmid=21149253 | doi=10.1093/neuonc/noq173 | pmc=PMC3064625 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21149253 }} </ref><ref name="pmid15977639">{{cite journal| author=Ohgaki H, Kleihues P| title=Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. | journal=J Neuropathol Exp Neurol | year= 2005 | volume= 64 | issue= 6 | pages= 479-89 | pmid=15977639 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15977639 }} </ref> | ||
===Age=== | ===Age=== |
Revision as of 14:42, 2 May 2019
Oligodendroglioma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Oligodendroglioma epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Oligodendroglioma epidemiology and demographics |
Risk calculators and risk factors for Oligodendroglioma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]
Overview
Oligodendroglioma, although rare, is the third most common glioma.[1] The incidence of oligodendroglioma and anaplastic oligodendroglioma is estimated to be 0.32 and 0.17 cases per 100,000 individuals in the United States, respectively.[2] Oligodendroglioma is a disease that tends to affect the middle-aged adult population.[1] Oligodendroglioma most commonly occurs in the 4th and 5th decade of life. Males are more commonly affected with oligodendroglioma than females. The male to female ratio is approximately 2 to 1.[3] Oligodendroglioma usually affects individuals of the Caucasian race. African American, Latin American, and Asian individuals are less likely to develop oligodendroglioma.[4]
Epidemiology and Demographics
Prevalence
- Oligodendroglioma, although rare, is the third most common glioma.[1]
- Oligodendroglioma accounts for 2%–5% of primary brain tumors and 5%–18% of all glial neoplasms.
Incidence
- The incidence of oligodendroglioma and anaplastic oligodendroglioma is estimated to be 0.32 and 0.17 cases per 100,000 individuals in the United States, respectively.[2][5]
Age
- Oligodendroglioma is a disease that tends to affect the middle-aged adult population.[1]
- Oligodendroglioma most commonly occurs in the 4th and 5th decade of life.
- The median age at diagnosis is 47 years.[6]
Gender
- Males are more commonly affected with oligodendroglioma than females. The male to female ratio is approximately 2 to 1.[3]
Race
- Oligodendroglioma usually affects individuals of the Caucasian race. African American, Latin American, and Asian individuals are less likely to develop oligodendroglioma.[4]
References
- ↑ 1.0 1.1 1.2 1.3 Epidemiology of oligodendroglioma. Dr Henry Knipe and Dr. Frank Gaillard et al. http://radiopaedia.org/articles/oligodendroglioma
- ↑ 2.0 2.1 McCarthy BJ, Rankin KM, Aldape K, Bondy ML, Brännström T, Broholm H; et al. (2011). "Risk factors for oligodendroglial tumors: a pooled international study". Neuro Oncol. 13 (2): 242–50. doi:10.1093/neuonc/noq173. PMC 3064625. PMID 21149253.
- ↑ 3.0 3.1 Simonetti G, Gaviani P, Botturi A, Innocenti A, Lamperti E, Silvani A (2015). "Clinical management of grade III oligodendroglioma". Cancer Manag Res. 7: 213–23. doi:10.2147/CMAR.S56975. PMC 4524382. PMID 26251628.
- ↑ 4.0 4.1 Patterns by Gender for Selected Histologies CBTRUS Statistical Report: NPCR and SEER Data from 2004-2006. CBTRUS.org 2015. http://www.cbtrus.org/2010-NPCR-SEER/CBTRUS-WEBREPORT-Final-3-2-10.pdf
- ↑ Ohgaki H, Kleihues P (2005). "Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas". J Neuropathol Exp Neurol. 64 (6): 479–89. PMID 15977639.
- ↑ Mørk SJ, Lindegaard KF, Halvorsen TB, Lehmann EH, Solgaard T, Hatlevoll R; et al. (1985). "Oligodendroglioma: incidence and biological behavior in a defined population". J Neurosurg. 63 (6): 881–9. doi:10.3171/jns.1985.63.6.0881. PMID 4056902.